Document Type : Original Article
Authors
- Razieh Zare 1
- Mohammad Ali Ranjbar 2
- Ava Ebrahimi 3
- Mahyar Malekzadeh 4
- Bijan Khademi 5
- Najmeh Savadi 6
1 Oral and Dental Disease Research Center, Dept. of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.
2 Dept. of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.
3 Student’s Research Committee, Biomaterial Research Center, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.
4 Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
5 Dept. of Otolaryngology, Khalili Hospital, Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
6 Dept. of Dental Public Health, School of Dentistry, Bushehr University of Medical Sciences, Bushehr, Iran.
Abstract
Background: The expression of CD73 antigen is associated with different prognoses in different carcinomas. However, few studies have assessed the level of this marker in squamous cell carcinoma (SCC) as the most common malignancy of the head and neck region.
Purpose: The aim of this study was to determine the serum levels of CD73 in patients with head and neck SCC to explain their association with clinicopathological parameters.
Materials and Method: This cross-sectional study was done on 60 samples taken from patients with head and neck SCC. A total of 28 healthy individuals were enrolled as the control group. Using the sandwich ELISA method, the serum levels of CD73 were measured. The data were statistically analyzed using the independent t-test and the Kruskal-Wallis test.
Results: The mean serum level of CD73 in the SCC patients (114.38 ng/ml, n=60) was almost similar to that of the healthy controls (137.22 ng/ml, n=28; p Value=0.098). The mean serum levels of CD73 were greater in patients with III/IV-stage tumors than in those with I/II-stage tumors (121.37±55.96 ng/ml, n=28 vs 108.27±39.44 ng/ml, n=32; p= 0.294). No correlation was found between the serum levels of CD73 and sex, age, tumor size, lymph node metastasis, and other organ metastasis.
Conclusion: The results of the current study revealed no significant relationship between the serum levels of CD73 and the clinicopathological factors in patients with head and neck SCC. These results suggest that the serum levels of CD73 may not be a useful biomarker for the recognition of the clinical behavior of head and neck SCC. However, the actual role of CD73 in SCC remains unclear and requires further research.
Keywords
- Regezi JA, Sciubba J, Jordan RC. Oral pathology: clinical pathologic correlations. 7th ed. Elsevier Health Sciences: St. Louis, Missouri; 2016.
- Donaldson M, Goodchild J, Wrobel M. Pharmacotherapy. Burket’s oral medicine. 12th ed. Shelton PMPH: USA; 2015. p. 448-450.
- Locally advanced squamous carcinoma of the head and neck [Internet]. 2014 Review of Cancer Medicines on the WHO List of Essential Medicines. 2014. Available at: https://www.who.int/selection_medicines/committees/expert/20/applications/Head-Neck.pdf.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424.
- Mafi N, Kadivar M, Hosseini N, Ahmadi S, Zare-Mirzaie A. Head and neck squamous cell carcinoma in Iranian patients and risk factors in young adults: a fifteen-year study. Asian Pac J Cancer Prev. 2012; 13: 3373-3378.
- Deady S, Sharp L, Comber H. Increasing skin cancer incidence in young, affluent, urban populations: a challenge for prevention. Br J Dermatol. 2014; 171: 324-331.
- Gatta G, Capocaccia R, Botta L. Descriptive epidemiology of the head and neck cancers in old patients. Front Oncol. 2023; 13: 1102236.
- Abrahão R, Perdomo S, Pinto LFR, Nascimento*de*Carvalho F, Dias FL, de*Podestá JRV, et al. Predictors of survival after head and neck squamous cell carcinoma in South America: the Inter change study. JCO Glob Oncol. 2020; 6: 486-499.
- Antonioli L, Pacher P, Vizi ES, Haskó G. CD39 and CD73 in immunity and inflammation. Trends Mol Med. 2013; 19: 355-367.
- Jiang T, Xu X, Qiao M, Li X, Zhao C, Zhou F, et al. Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers. BMC Cancer. 2018; 18: 267.
- Stagg J, Smyth M. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene. 2010; 29: 5346-5358.
- Allard D, Allard B, Gaudreau PO, Chrobak P, Stagg J. CD73–adenosine: a next-generation target in immunooncology. Immunotherapy. 2016; 8: 145-163.
- Beavis PA, Stagg J, Darcy PK, Smyth MJ. CD73: a potent suppressor of antitumor immune responses. Trends Immunol. 2012; 33: 231-237.
- Yang Q, Du J, Zu L. Overexpression of CD73 in prostate cancer is associated with lymph node metastasis. Pathol Oncol Res. 2013; 19: 811-814.
- Gaudreau PO, Allard B, Turcotte M, Stagg J. CD73-adenosine reduces immune responses and survival in ovarian cancer patients. Oncoimmunology. 2016; 5: e1127496.
- Koivisto MK, Tervahartiala M, Kenessey I, Jalkanen S, Boström PJ, Salmi M. Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer. Carcinogenesis. 2019; 40: 84-92.
- Hasmim M, Berchem G, Janji B. A role for EMT in CD73 regulation in breast cancer. Oncoimmunology. 2022; 11: 2152636.
- Sun P, Zheng X, Li X. The Effects of CD73 on Gastrointestinal Cancer Progression and Treatment. J Oncol. 2022; 2022: 4330329.
- Miyazaki M, Aoki M, Okado Y, Koga K, Hamasaki M, Nakagawa T, et al. Highly expressed tumoral emmprin and stromal CD73 predict a poor prognosis for external auditory canal carcinoma. Cancer Sci. 2020; 111: 3045-3056.
- Lu XX, Chen YT, Feng B, Mao XB, Yu B, Chu XY. Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma. World J Gastroenterol. 2013; 19: 1912-1918.
- Gao ZW, Wang HP, Lin F, Wang X, Long M, Zhang HZ, et al. CD73 promotes proliferation and migration of human cervical cancer cells independent of its enzyme activity. BMC Cancer. 2017; 17: 135.
- Supernat A, Markiewicz A, Welnicka-Jaskiewicz M, Seroczynska B, Skokowski J, Sejda A, et al. CD73 expression as a potential marker of good prognosis in breast carcinoma. Appl Immunohistochem Mol Morphol. 2012; 20: 103-107.
- Turcotte M, Spring K, Pommey S, Chouinard G, Cousineau I, George J, et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. Cancer Res. 2015; 75: 4494-4503.
- Morello S, Capone M, Sorrentino C, Giannarelli D, Madonna G, Mallardo D, et al. Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. J Transl Med. 2017; 15: 244.
)